EtNova Therapeutics develops small molecule-based therapeutics targeting hepatocellular carcinoma and ischemic stroke, providing healthcare professionals with effective treatment options for these critical conditions. Their pipeline includes ETN101 for liver cancer, ETN102 for stroke prevention, and ETN103 for degenerative brain diseases, addressing significant unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Hepatocellular carcinoma and ischemic stroke lack sufficiently effective treatment options, leading to poor patient outcomes and significant unmet medical needs. Current therapies often have limited efficacy or severe side effects, highlighting the need for novel therapeutic interventions. Degenerative brain diseases also present a significant challenge with few effective treatments available.
Solution
EtNova Therapeutics develops small molecule-based therapeutics designed to address hepatocellular carcinoma, ischemic stroke, and degenerative brain diseases. Their pipeline includes ETN101, a targeted anti-cancer agent for liver cancer; ETN102, a treatment for ischemic stroke; and ETN103, a therapeutic for degenerative brain diseases. These molecules are designed to provide healthcare professionals with more effective and targeted treatment options for these conditions.
Target Audience
The primary target audience includes healthcare professionals, specifically oncologists and neurologists, treating patients with hepatocellular carcinoma, ischemic stroke, and degenerative brain diseases.
Features
- ETN101: Small molecule therapeutic targeting hepatocellular carcinoma.
- ETN102: Small molecule therapeutic for the treatment of ischemic stroke.
- ETN103: Small molecule therapeutic targeting degenerative brain diseases.
- Focus on developing targeted therapies to improve efficacy and reduce side effects.